FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
MedPage Today on MSN

First drug for deadly transplant complication gets FDA's blessing

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

Omeros Gets FDA Approval of Yartemlea

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
TipRanks on MSN

Omeros announces FDA-approved YARTEMLE for treatment of TA-TMA

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...
Medical Dialogues

FDA Approves First Treatment for HSCT-Associated Thrombotic Microangiopathy

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...
JSTOR Daily

Origin of the Classical Complement Pathway: Lamprey Orthologue of Mammalian C1q Acts as a Lectin

Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. 27 (Jul. 6, 2004), pp. 10127-10131 (5 pages) The lectin complement pathway in innate immunity is closely ...
Forbes

An Ancient Form Of Immunity Protects Many Against Covid-19 Today

Figure 1: Mannose-binding lectin (blue strands) can bind to sites on the SARS-Cov-2 spike protein on the cell membrane. One of the most striking features of the SARS-CoV-2 pandemic is that across all ...